Best Life Sciences & BioTech Brands 2026

German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and

Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbu

World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clin

Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Geno

Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and p

Nasdaq-listed (PRME). $191M cash runway into 2027. IND for Wilson's Disease H1 2026. AATD IND mid-20

Raised $381M IPO on Nasdaq (Feb 2026, EIKN). Proprietary RESOLFT super-resolution microscopy tracks

Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fi

Precision oncology company emerged from stealth Apr 2026 with $100M oversubscribed Series A co-led b

AI protein design platform combining language models with lab automation; active learning cycles for

Received up to $40.7M ARPA-H award (Oct 2025). Polymeric nanoparticle platform to reprogram immune c

Raised $250M Series B (Jan 2026). $650M+ total raised. Mirador360 genetics-first platform. 10+ clini

Raised $100M Series A extended ($60M + $40M add-on after clinical data) from Atlas, Frazier, Access

Full-stack AI biologics company raised $787M in Mar 2026 backed by Sanofi, Pfizer/Hillhouse, and DST

Raised $50M Series A (May 2025) co-led by Accel and Insight Partners. Cuts trial costs 50%, enrollme

Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli L

FDA-cleared IND for CRISPR-edited pig kidney (ESKD Phase 1/2/3). First patient dialysis-free at 7+ m

$40M Series A. First patient dosed in Phase 1 for RLS-1496 — first GPX4 modulator targeting patholog

Raised $153M Series B (Aug 2025). $256M total. Programmable mRNA with SignalLock tumor-sensing logic

Raised $105M oversubscribed Series C (Mar 2026) led by Morningside Ventures. HOPE pivotal trial full

Umoja Biopharma raised $300M+ for its lentiviral vector CAR-T platform that delivers cancer-fighting

Gameto raised $70M Series B in 2024 for its stem cell technology that dramatically reduces IVF stimu

Finch Therapeutics develops microbiome-based medicines targeting the gut-brain and gut-immune axis w

Positive 48-week Phase 2 BEHOLD data for UBX1325 in DME published in NEJM Evidence. Single-injection

Raised $95M total ($50M Series A Jan 2026 + $45M extension Mar 2026) from SR One, Vida, RA Capital,

Microbiotica raised $105M Series C in 2025 for its gut microbiome platform linking bacterial strains

Vancouver-based antibody discovery platform with 104+ partner programs; $75M FY2025 revenue. Expandi

Beam Therapeutics develops precision genetic medicines using base editing technology that makes sing

Raised £50M ($67M) oversubscribed Series B (Sep 2025). First participants dosed in Phase 1 of NRG505

AI protein design company released OpenCRISPR-1, the first gene editor designed entirely by AI; rais

Aevice Health raised $30M Series B in 2025 for its AI-powered wearable respiratory monitor that cont

Infant Bacterial Therapeutics (IBT) is developing live biotherapeutic Lactobacillus reuteri DSM17938

Nautilus Biotechnology is building a single-molecule proteomics platform to map and quantify the ful

Sidewinder Therapeutics raised $100M Series A in 2025 for its conditional activation platform that c

Verdiva Bio raised $200M in 2025 for next-generation oral GLP-1 receptor agonists designed to match

Raised $180M Series A (Jan 2025). CM313 achieved 95% response rate in treatment-refractory ITP in NE

Sana Biotechnology develops engineered cell and gene therapies with fusogen delivery technology to t

Kailera Therapeutics (Hengrui spinout) raised $1B+ and filed a US IPO (Mar 2026); its lead GLP-1/GIP

YC-backed AI company raised $48M Series A co-led by a16z Bio and GV in Feb 2026; builds digital twin

Launched with $101M Series A (Third Rock, Atlas, GV, RA Capital). TRCN-1023 (ASO for UNC13A mRNA spl

Raised $135M Series B led by Sanofi Ventures and EQT (Jun 2025). First patient dosed in Phase 1/2 fo

Cambridge MA precision oncology biotech using Dynamo platform to exploit protein motion for drug des

Nasdaq-listed (ANRO). Raised $120M PIPE (2026) to fund ALTO-207 Phase 2b. FDA Fast Track for ALTO-10

Absci is an AI drug creation company that combines generative AI with a synthetic biology platform t

Raised $100M Series B. Jennifer Doudna co-founder. Sanofi + Eli Lilly partnerships. STX-1150 (PCSK9

Raised $107M Series B (Jan 2026) co-led by J&J Ventures and Google Ventures. EpiTAC targets membrane

Raised $200M oversubscribed (Nov 2025) backed by Hong Kong Investment Corporation and sovereign weal

Raised €11M Series A (Jan 2026). FDA-cleared in 2025. Detects 96%+ of congenital heart defects in pr

Physics-based molecular simulation platform used by 1,700+ organizations. Q3 2025 software revenue u

Raised $120M oversubscribed (Nov 2025) with Merck & Co. as new equity investor. $321M total. CloakLi

Drug discovery company founded by Daphne Koller integrating ML with high-throughput biology; raised

NEOK Bio emerged from stealth in 2025 with $80M in funding targeting neuroinflammation pathways in A

Seres Therapeutics develops microbiome therapeutics, including Vowst, the first FDA-approved oral mi

Raised $29M Series A. Acquired ARMMs vesicular delivery tech (Mar 2025). Delivers mRNA cocktails tha

Closed $80M Series D (Apr 2026). FDA-cleared IND for ER-100 in optic neuropathies (Jan 2026). Phase

Ophthalmic robotics company raised $125M Series B in Jun 2025; first human cataract trials launching

Nasdaq IPO Feb 2026 (~$200M raised, ~$780M valuation, ticker AGMB). Positive Phase 2a data for ontun

Raised $52M Series A extension (Feb 2026) from a16z as new investor — total $217M. ARC101 (bispecifi

Lyell Immunopharma develops next-generation CAR-T cell therapies designed to overcome T cell exhaust

Largest-funded pure-play longevity startup raising $1B Series A at $5B valuation; Sam Altman-backed;

Raised $60M Series A (Jan 2026) led by Ouroboros Capital. Mayo Clinic spinout. Engineered pigs as bi

Alveus Therapeutics raised $150M Series A in 2025 for inhaled mRNA therapeutics targeting pulmonary

Leading single-cell genomics platform; $642M FY2025 revenue. Chromium and Visium spatial platforms p

Pioneer of single-molecule real-time (SMRT) long-read sequencing; Revio system targets clinical and

Raised $157M oversubscribed Series C (Oct 2025) led by Sofinnova and Qatar Investment Authority. Sut

Epigenome editing company silencing disease-causing genes without permanent DNA cuts; raised $175M S

Cradle provides an AI platform for protein engineering that accelerates the design of improved enzym

Verve Therapeutics develops single-course gene editing medicines for cardiovascular disease, aiming

Muna Therapeutics raised $75M in 2024 targeting microglial biology in Alzheimer's disease, using iPS

Emerged from stealth with $100M (Dec 2025) backed by Gates Foundation, SR One, Abingworth. PRINT LNP

Dotmatics (acquired by Insightful Science 2024) serves 1M+ researchers at 10,000+ organizations; R&D

UK nanopore sequencing pioneer with portable MinION device; £223M FY2025 revenue (+24% constant curr

$274M total raised including $92M Series C with Bristol Myers Squibb. Phase 1/2 active for BE-101 in

Raised $130M Series B (Kleiner Perkins) + $45M from Eli Lilly at $1.62B valuation. First demonstrate

Raised $39M (Feb 2026, doubled from $21M Series A). Brain-shuttle + RNAi delivery for genetic Alzhei

Synthetic DNA manufacturing platform on silicon chips; $376M FY2025 revenue (+20% YoY). Supplies syn